Related Experiment Video

Updated: Jul 9, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Therapeutic potential of directed tyrosine kinase inhibitor therapy in sarcomas

Audrey C Shor1, Samuel V Agresta, Gina Z D'Amato

  • 1Sarcoma Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA. audrey.shor@moffitt.org

Cancer Control : Journal of the Moffitt Cancer Center
|December 21, 2007
PubMed
Abstract

Insights

Tyrosine kinase inhibitors (TKIs) show promise for treating rare sarcomas. These targeted therapies may improve outcomes for patients with soft tissue sarcoma, complementing existing treatments.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Sarcomas are rare cancers originating from connective tissues.
  • Limited effective treatment options exist for most sarcoma subtypes.

Purpose of the Study:

  • To review the therapeutic potential of targeted tyrosine kinase inhibitors (TKIs) in sarcoma treatment.
  • To explore TKIs beyond gastrointestinal stromal tumors.

Main Methods:

  • Literature review of antibody-based strategies and small molecule inhibitors.
  • Focus on targeted agents for non-gastrointestinal stromal tumor sarcomas.

Main Results:

  • Tyrosine kinases (TKs) are frequently altered (mutated/overexpressed) in sarcomas.
  • Targeting TKs presents a promising therapeutic strategy.
  • TKIs may enhance the efficacy of current sarcoma treatments.

Conclusions:

  • TKIs like imatinib, sunitinib, and sorafenib offer new therapeutic avenues.
  • These agents are promising for managing patients with soft tissue sarcoma.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...